Table 2 Clinical course before and after SGLT-2 inhibitor administration
| Â | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
|---|---|---|---|---|---|
Body weight (Kg) | 69.0/67.8 | 73.4/83.3 | 73.4/73.3 | 89.1/86.2 | 99.9/98.2 |
Waist circumference (cm) | 92/90 | 104/106 | 91/89 | 94/91 | 112/111 |
SBP (mmHg) | 159/103 | 140/124 | 132/131 | 135/125 | 126/139 |
SBP (mmHg) | 79/60 | 72/66 | 76/78 | 79/77 | 85/87 |
Cr (mg/dL) | 1.69/1.71 | 1.40/1.70 | 2.16/2.37 | 1.33/1.25 | 1.89/1.67 |
eGFR (ml/min/1.732) | 32.8/32.1 | 39.5/33.9 | 25.9/23.4 | 45.0/47.9 | 32.4/36.0 |
UA(mg/dL) | 5.1/5.4 | 4.2/4.0 | 4.4/3.9 | 5.5/5.8 | 4.1/5.5 |
ALT (IU/L) | 9/8 | 73/51 | 16/9 | 26/21 | 39/36 |
γ-GTP (IU/L) | 11/9 | 89/58 | 57/40 | 30/24 | 40/37 |
TG (mg/dL) | 121/116 | 188/133 | 248/248 | 112/76 | 173/99 |
HbA1c (%) | 6.8/6.4 | 6.0/5.9 | 5.5/5.6 | 7.6/7.1 | 6.0/5.8 |
UACR (mg/gCr) | 135.7/27.7 | 35.8/10.8 | 790.0/650.0 | 24.0/19.1 | 46.9/23.6 |
Observation period (months) | 24 | 18 | 18 | 9 | 8 |